(Vietnam Insider) – Russia has announced that its cancer vaccine has successfully completed preclinical testing, delivering strong results in both safety and effectiveness. The news was shared by Veronika Skvortsova, head of the Federal Medical-Biological Agency (FMBA), during the Eastern Economic Forum (EEF).
Skvortsova explained that the vaccine has been under development for years, with the past three years focused on mandatory preclinical studies. “The vaccine is now ready for use, and we are awaiting official approval,” she said.
According to the FMBA, tests showed the vaccine was safe even with repeated doses, while also achieving significant outcomes: tumor shrinkage and slower progression in 60% to 80% of cases, depending on the type of cancer. Researchers also reported improved survival rates among test subjects.
Early Targets and Expansion
The vaccine’s initial target will be colorectal cancer. At the same time, research teams have also made promising progress in developing vaccines for glioblastoma and certain types of melanoma, including ocular melanoma, which are already at advanced stages of development.
Personalized mRNA Cancer Vaccine
In August, Alexander Gintsburg, Director of the Gamaleya Research Institute of Epidemiology and Microbiology, announced that the first patients in Russia may soon receive a new AI-powered cancer vaccine.
This vaccine, based on mRNA technology, is personalized for each patient. It is designed to attack malignant tumors using the individual’s genetic profile. Clinical trials are set to begin within months at two leading oncology centers in Moscow – the Hertsen Research Institute and the Blokhin Cancer Center.
“The Ministry of Health has approved a trial plan involving melanoma patients,” Gintsburg said. “This vaccine is completely personalized, made specifically for each patient based on their tumor data, and cannot be used for anyone else.”
AI-Accelerated Development
The project began in mid-2022 using mRNA technology. The vaccine works by training the immune system to identify tumor-specific antigens and destroy cancer cells throughout the body.
Originally intended for melanoma, the vaccine has shown encouraging results in animal testing and limited human trials. Thanks to artificial intelligence, the process—from analyzing a tumor to producing a personalized vaccine—can be completed in just one week.
Related
Discover more from Vietnam Insider
Subscribe to get the latest posts sent to your email.
Source: Vietnam Insider